Skip to NavigationSkip to content

Pfizer launches pilot delivery programme for its coronavirus vaccine

Published on 17/11/20 at 12:43pm
Photo by Lauri Silvennoinen

Pfizer is set to launch its first delivery programme for the COVID-19 vaccine it developed with BioNTech. It will be located in multiple sites across America; the company said it has selected New Mexico, Tennessee, Rhode Island and Texas for the programme because of their differences in size and immunisation infrastructure. 

This follows last week's news that one of the Pfizer-BioNTech vaccine candidates was over 90% effective in immunising patients to coronavirus. 

“The four states included in this pilot programme will not receive vaccine doses earlier than other states by virtue of this pilot, nor will they receive any differential consideration,” Pfizer said in a statement. “We are hopeful that results from this vaccine delivery pilot will serve as the model for other US states and international governments, as they prepare to implement effective COVID-19 vaccine programmes.”

The vaccine must be shipped and stored at -70°C, which is below the standard temperature vaccines are generally stored at. This has many experts concerned about the difficulties of widespread distribution of the vaccine. These fears have been alleviated somewhat due to Moderna’s coronavirus vaccine being 94.5% effective in data released by the company. This vaccine does not require ultra-cold freezing, making transportation and distribution easier. 

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches